THE INLINE META ANALYSIS
Evaluation of the optimal suture technique andmaterial for abdominal fascia closure after electivemidline laparotomy.
5 systematic reviews and 14 trials including7711 patients were analysed.
there is a lower change of developing incisional hernia ifthe abdominal fascia is closed with a continuous techniqueusing slowly absorbable suture material in comparison withinterrupted technique with rapid-absorbable suture material.
THE INSECT STUDY
Comparison of the interrupted technique using a rapidlyabsorbable braided suture with the continuous technique usingdifferent slowly absorbable monofilament sutures, focusing onthe incidence of incisional hernia rate 1 year postoperatively
Multicenter randomized controlled trial with 3 parallel groupsincluding 625 patients.
The incidence of incisional hernias and the frequency of woundinfection was higher than expected in all groups. New conceptsneed to be developed and studied to substantially reduce thefrequency of incisional hernias.
THE MULTIMAC STUDY
Evaluation of Monomax suture performance for transverseand midline abdominal wall closure in daily clinical practiceeven in high risk patients (no BMI limit).
A multicenter, international, prospective, observational,single-arm study including 200 patients.
The application of Monomax is safe and effective, includingfor the closure of transverse abdominal wounds.
The low short-term complication rates (burst abdomen andwound infection) observed using Monomax suture in obese,AAA and diabetic patients in the current study indicate abeneficial clinical outcome also for high-risk patients.
THE ISSAAC STUDY
Assessment of the safety and efficacy of the newultra-long-term absorbable, elastic monofilamentsuture material Monomax for abdominal wall closure.
Historically controlled, single-arm, multicentreprospective study with 150 patients. The controlgroup consisted of 141 patients from the INSECTstudy receiving a continuous slowly absorbablepolydioxanone suture (PDO).
Primary endpoint: Burst abdomen and , or woundinfection rate until day of discharge:
AKSHAR PHARMA
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |